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processes, for example, by identifying
antigen presentation and T-cell activation
and/or differentiation. Our results addi-
tionally underscore contributions from
the JAK-STAT signaling and the cos-
timulatory pathway. These particular
processes are capable of being modu-
lated with available therapeutics, which
we are currently studying within the
context of clinical trials in AA, using JAK
inhibitors and abatacept, respectively.
Furthermore, these genes could be useful
in our development of a biomarker panel,
allowing us to prioritize transcriptional
changes that occur over particular dis-
ease trajectories and/or during a thera-
peutic response. Finally, evidence
obtained in this study can be integrated
with results from next-generation
sequencing, providing a framework for
the interpretation of variants harbored by
patients and laying a foundation for pre-
cision medicine in AA.
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Se´zary syndrome (SS) and eryth-
rodermic mycosis fungoides (EMF) are
part of a broader spectrum of eryth-
rodermic cutaneous T-cell lymphoma.
The revised ISCL/EORTC staging iden-
tifies three types of blood involvement:
B0 (circulating Se´zary cells [CSC] 
5%), B1 (CSC > 5% but <1,000/mm3),
and B2 (CSC > 1,000/mm3) (Olsen
et al., 2007). Only B2 are recognized
as SS, whereas B0 and B1 are consid-
ered as EMF. EMF is defined as eryth-
roderma with papules and plaques
greater than 80% of the body surface
area associated with suggestive histol-
ogy of cutaneous T-cell lymphoma in
accordance with Olsen et al. However,patients with EMF must not meet SS
criteria, namely a CSC count > 1,000/
mm3, a CD4/CD8 ratio  10, a
CD4þCD7 lymphocyte population 
40%, or a CD4þCD26 population 
30% (Olsen et al., 2007; Willemze
et al., 2005). Several molecular
markers have been specifically identi-
fied in the blood of patients with SS,
including CD158k/KIR3DL2, the tran-
scription factor Twist, T-plastin (PLS3),
and CD335/NKp46 (Bensussan et al.,
2011; Bouaziz et al., 2010; Michel
et al., 2013; Nebozhyn et al., 2006;
Tang et al., 2010; Van Doorn et al.,
2004). Of interest, our previous results
clearly evidenced that their combina-
tion allows diagnosis of 100% ofuntreated patients with SS (Michel
et al., 2013).
Herein, this combination of blood
biomarkers was assessed in all the
patients with EMF diagnosed from
three French dermatological centers
during the last decade to determine
whether EMF covers a set of various
stages. To this aim, we compared pa-
tients with EMF with the cohort of
patients with SS (n ¼ 81, mean age
69.5 years [22e88 years]) and of
healthy donors (n ¼ 12, mean age
33.2 years [23e49 years]) previously
published (Michel et al., 2013). The
local ethics committees approved the
study and all the subjects gave written
informed consent. Thirty-one patients
were included (20 males, 11 women),
with a median age of 64.2 years
(30e85 years) at diagnosis: 13 patients
were B0 and 18 patients were B1, with
a mean  SD CSC absolute count ofwww.jidonline.org 317
Figure 1. Flow cytometry analysis and blood biomarker qPCR values in EMF patients. (a) Flow cytometry analysis of CD3þCD4þKIR3DL2þ cells in one
representative patient with EMF at stage B1. Percentage of CD3þCD4þ T cells was ascertained among fresh peripheral blood mononuclear cell gate (left), and
then KIR3DL2 expression was evaluated on the CD3þCD4þ T cells by immunofluorescence staining with a monoclonal phycoerythrineconjugated KIR3DL2
antibody (Miltenyi) (right). The blue line (empty histogram) indicates staining with a control isotype monoclonal irrelevant antibody. (b) Individual values of each
blood biomarker in B0 and B1 patients. All samples were run in duplicate. The single data points in (b) represent the mean value of the duplicate for each blood
biomarker for each individual patient. The bars represent median values, and the error bars are the interquartile range. Mann-Whitney test: *P < 0.05. EMF,
erythrodermic mycosis fungoides.
Table 1. Percentages of blood biomarker positivity in B0 (n [ 13) and B1 EMF (n [ 18), as compared with B2
(Se´zary syndrome) patients (n [ 81) and healthy donors (n [ 12), using determination of the positive arbitrary
threshold value obtained by q-RT-PCR at 95% significance: 25, 10, 5, and 5 for KIR3DL2, Twist, T-plastin, and
NKp46, respectively
Biomarker
positivity
KIR3DL2
% (number of positive
patients/total)
Twist
% (number of positive
patients/total)
T-plastin
% (number of positive
patients/total)
NKp46
% (number of positive
patients/total)
Any blood biomarker
% (number of positive
patients/total)
B0 23 (3/13) 15 (2/13) 8 (1/13) 0 (0/13) 31 (4/13)
B1 78 (14/18) 33 (6/18) 44 (8/18) 18 (3/17) 78 (14/18)
B2 ¼ SS 84 (68/81) 91 (73/81) 87 (70/81) 28 (23/81) 100 (81/81)
Healthy donors 0 0 0 0 0
When biomarker expression was positive expression, the mean  SD (min-max) mRNA expression levels of biomarkers for KIR3DL2, Twist, T-plastin, and
NKp46 were 300  403 (45e1,444), 2,057  4,256 (11.4e10,738), 223  357 (7.1e1,075), and 14.2  7 (6.6e18.1), respectively, in B1 patients and
408  298 (129e714), 1,155  1,406 (161e2,149), 537, and no NKp46 positivity, respectively, in B0 patients.
Abbreviations: EMF, erythrodermic mycosis fungoides; SS, Se´zary syndrome.
C Hurabielle et al.
Se´zary Blood Markers in Erythrodermic Mycosis Fungoides
318247/mm3  100. In 11 patients, EMF
was inaugural of the disease and blood
analysis was done right at the begin-
ning of the disease before any treat-
ment. In the remaining 20 patients,
there was first a localized MF, which
evolved within a median of 3.5 yearsJournal of Investigative Dermatology (2016), Volum(0.2e20 years). The latter had already
received treatments before biomarker
analysis (skin-directed therapies only
n ¼ 12, systemic therapy n ¼ 8).
All nine patients with EMF who were
investigated for CD26 and CD7 expres-
sion had less than 30% CD4þCD26e 136and 40%CD4þCD7 T cells. Biomarker
gene expression was evaluated by
quantitative PCR (qRT-PCR, SYBR green
technology, ABI PRISM7300 Real-time
PCR System) on CD4þ T cells isolated
by positive magnetic-activated cell
sorting (Miltenyi, Bergisch Gladbach,
C Hurabielle et al.
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(Michel et al., 2013). Quantification of
the target gene expression was done
using the comparative cycle threshold
(Ct) method, using b2 microglobulin as
housekeeping gene (Ct¼Ct sampleCt
b2 microglobulin). The mRNA expres-
sion of each biomarker was obtained as
2(DDCts) values (arbitrary units AU).
Moreover, surface KIR3DL2 expression
was assessed using flow cytometry
analysis on CD3þCD4þ T cells, as
shown for one representative patient in
Figure 1a.
Comparisons of the qualitative vari-
able were done with a c2 test.
Percentages of blood biomarker pos-
itivity are shown in Table 1, and median
expression and individual values are
reported in Figure 1.
We observed that among all patients
with EMF, 18 of 31 (58%) were positive
for the expression of blood biomarkers.
If detailed in B0 and B1 types, it clearly
appears that B1 patients expressed
significantly more blood biomarkers
than B0 patients (78% vs. 31%, P ¼
0.013). B1 expressed significantly less
blood biomarkers than patients with SS
(78% vs. 100%, P < 0.001), as shown
in Table 1. KIR3DL2 was the most
frequently detected blood biomarker
(89%), and its expression was
confirmed by flow cytometry analysis
with a median surface expression of
51% (range 7.5e91.2%).
Percentages of patients with
biomarker positive expression detailed
one by one were lower in B0 patients
than in B1 patients, statistically signifi-
cant for KIR3DL2 and T-plastin (P ¼
0.011 and 0.045, respectively), and
lower in B1 patients than in patients
with SS, statistically significant for Twist
and T-plastin (P < 0.001 for both).
Of interest, our results also demon-
strate that 31% of patients with EMF do
have Se´zary biomarkers in the absence
of CSC. These results contrast with
those obtained with healthy donors
(mean value  SD of T-plastin, Twist,
KIR3DL2, and NKp46 mRNA expres-
sion: 2.4  2.5, 6.6  8, 22.5  20.4,
and 2.6  2.5, respectively, in healthy
CD4þ T cells) (Michel et al., 2013).
Moreover, the fact that B1 patients
expressed more blood biomarkers than
did B0 patients is interesting because
B1 are considered as pre-Se´zary, having
a poorer prognosis than B0 (Scarisbricket al., 2014). Indeed, in our study, with
a median follow-up of 1.6  2.2 years
(0.5e9 years), we have observed that
six patients evolved toward SS in 1.2
years in median (range 0.5e2.5 years),
all of them B1, and all of them
expressing blood biomarkers.
Thus, biomarkerpositivitymight reflect
appearance of the first events leading to
a more aggressive disease, namely SS.
Moreover, those expressions might favor
disease progression because the biolog-
ical functions of each Se´zary biomarker
have been shown to promote resistance
to apoptosis of CD4þ tumor T cells,
and may have significant involvement
in the progression of Se´zary syndromes.
In particular, it has been recently
demonstrated that KIR3DL2 acts as an
inhibitory coreceptor in Se´zary cells,
promoting resistance to activation-
induced cell death (Thonnart et al.,
2014). Twist might promote solid
tumor progression by blocking p53
and inhibiting c-myc-induced apoptosis
(Goswami et al., 2012; Maestro et al.,
1999). Constitutive T-plastin expression
in cutaneous T-cell lymphoma was
shown to be linkedwithmigration and to
confer resistance to apoptosis induced by
antineoplastic agents, such as etoposide,
and T-plastin downregulation restored, in
part, drug sensibility (Be´gue´ et al., 2012).
Although the pathogenic roleofNKp46 is
poorly understood, it has been demon-
strated that it exhibited a function of
inhibitory coreceptor able to interfere
with the processes governing the CD3-
dependent proliferation of Se´zary cells
(Bensussan et al., 2011).
Our present results suggest that blood
biomarker expression may partially
reflect clinical evolution of EMF from
B0 to B2. This strongly argues for a
spectrum of EMF up to SS.
However, in the future, it will be of
major interest to perform an interna-
tional collaborative prospective study
within the framework of the Cutaneous
Lymphoma International Consortium
(CLIC study) (Scarisbrick et al., 2015) to
determine whether the expression of
blood biomarkers may have prognostic
value for an evolution toward SS. It
would also be interesting to determine
whether treatments administered to pa-
tients with EMF may have an impact on
the detection of blood biomarkers, and
might allow us to decrease EMF evolu-
tion toward the B2 stage.ORCID
Charlotte Hurabielle: http://orcid.org/0000-0002-
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Dystrophic epidermolysis bullosa
(DEB) is a congenital inherited blis-
tering disorder caused by mutations in
COL7A1, the gene encoding collagen
VII (COL7), which is a major struc-
tural component of anchoring fibrils
of the hemidesmosome. COL7 protein
comprises a central triple helical
domain flanked by a 145 kDa non-
collagenous amino-terminal domain
(NC1) and a 30 kDa carboxyl-
terminal domain (Burgeson, 1993).
DEB shows either autosomal domi-
nant (DDEB; OMIM#131750) or
recessive (RDEB; OMIM#226600) in-
heritance (Fine et al., 2014). In
contrast, epidermolysis bullosa
acquista (EBA) is a chronic, autoim-
mune, subepidermal blistering skin
disease with circulating IgG anti-
bodies against COL7 (Kim and Kim,
2013). In skin of patients with EBA,
linear deposition of IgG and C3 along
the dermal-epidermal junction (DEJ) is
evident with direct immunofluores-
cence; additionally, indirect immuno-
fluorescence with patient sera shows
linear deposition of IgG along the
dermal side of the DEJ on 1 M NaCl
split skin of normal control in-
dividuals. In most cases of EBA, epi-
topes of the auto-antibodies are
within the NC1 domain of COL7
(Lapiere et al., 1993). Interestingly,
anti-COL7 antibodies can begenerated in patients with RDEB
(Pendaries et al., 2010; Tampoia
et al., 2013; Woodley et al., 2014),
or DEB pruriginosa, which is an
allelic disorder of DDEB
(OMIM#604129) (Jedlickova et al.,
2012). Besides these findings,
whether DEB and EBA can coexist in
a single individual is largely un-
known. Here, we describe a rare case
of DDEB complicated by EBA.
We have seen a three-generation
Japanese family with DDEB at Niigata
University Hospital (Figure 1a). All
three affected individuals in the family
showed blister formations on their
hands and feet during early childhood,
whereas other skin areas and oral mu-
cosa were unaffected. The skin symp-
toms improved with aging and resulted
in scar formation and dystrophic nails
(Figure 1bed). After obtaining institu-
tional approval of experiments and
written informed consent from the pa-
tients, we performed direct sequencing
analysis and identified a recurrent
heterozygous missense mutation
c.7868G>A (p.Gly2623Asp) in the
COL7A1 gene of all three affected in-
dividuals (Supplementary Materials and
Methods online) (Figure 1e). On the
basis of previous reports of DDEB with
the identical mutation (Varki et al.,
2007) or other missense mutations at
the amino acid position 2623
(Christiano et al., 1995; Sawamuraet al., 2006; Varki et al., 2007), we
expected a good prognosis for the
affected individuals in this family.
To our surprise, however, the eldest
patient in the family (I-1; Figure 1a)
eventually showed bullae and subse-
quent scar formation all over her body,
including oral mucosa at the age of 63
(Figure 1feh). Skin biopsy from her left
arm revealed subepidermal bulla for-
mation with dense infiltration of lym-
phocytes, eosinophils, and neutrophils
(Figure 1i). Although circulating auto-
antibodies against the NC16a domain
of 180 kDa bullous pemphigoid antigen
were not evident in blood test, we
postulated that she might suffer from an
autoimmune blistering disease. To test
this hypothesis, we conducted a series
of analyses with samples of this pa-
tient’s skin and serum (Supplementary
Materials and Methods). Direct immu-
nofluorescence with skin sections from
this patient revealed linear deposition
of IgG and C3 at the DEJ (Figure 1j; data
not shown). In addition, indirect
immunofluorescence with 1 M NaCl
split normal human skin sections and
the patient’s serum clearly demon-
strated linear deposition of IgG at the
dermal side of the DEJ (Figure 1k),
suggesting that the antigen recognized
by the auto-antibodies localized below
the lamina lucida. Strikingly, Western
blot analysis with the patient’s serum
showed a 290 kDa fragment in dermal
extracts from a control individual,
which corresponded to the molecular
weight of COL7 (Figure 2a). By
contrast, the patient’s serum did not
recognize any component of laminin
